Mitsukuchi M, Ikemoto T, Taguchi M, Higuchi S, Abe S, Yasui H, Hatayama K
Research Center, Taisho Pharmaceutical Co., Ltd., Saitama, Japan.
Chem Pharm Bull (Tokyo). 1990 Mar;38(3):692-7. doi: 10.1248/cpb.38.692.
As part of our search for new topical antiinflammatory agents, a series of corticosteroid 17-(alkylthio)- and methoxyalkanoate derivatives was prepared and tested for vasoconstrictive activities. Several compounds were proved to have activity superior or comparable to that of 9 alpha-fluoro-11 beta,21-dihydroxy-16 beta-methyl-17 alpha-valeryloxy-1,4-pregnadiene-3,20-dione (betamethasone 17-valerate, BV). Among these compounds, 21-chloro-11 beta-hydroxy-17 alpha-(methylthio)acetoxy-4-pregnene-3,20-dione (5Aa) was found to have the most potent activity, being more active than BV. The structure-activity relationships of the series revealed that introduction of a (methylthio)acetate function into the 17-position as well as the 21-position of corticosteroids was effective for enhancing the topical antiinflammatory activity.
作为我们寻找新型局部抗炎药的一部分,我们制备了一系列皮质类固醇17-(烷硫基)-和甲氧基链烷酸酯衍生物,并测试了它们的血管收缩活性。已证明几种化合物的活性优于或与9α-氟-11β,21-二羟基-16β-甲基-17α-戊酰氧基-1,4-孕二烯-3,20-二酮(倍他米松17-戊酸酯,BV)相当。在这些化合物中,发现21-氯-11β-羟基-17α-(甲硫基)乙酰氧基-4-孕烯-3,20-二酮(5Aa)具有最强的活性,比BV更具活性。该系列的构效关系表明,在皮质类固醇的17位以及21位引入(甲硫基)乙酸酯官能团对于增强局部抗炎活性是有效的。